相关实验视频

Updated: Jun 4, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

在非小细胞肺癌中准C797S突变及其他突变 - - 一个小型综述

Wolfram C M Dempke¹, Klaus Fenchel²

¹University of Munich, Medical Clinic III, Campus Grosshadern, Munich, Germany.

Translational cancer research

|December 19, 2024

概括

像BDTX-1535这样的第四代EGFR抑制剂对非小细胞肺癌 (NSCLC) 的不常见突变和耐药性有希望. 这些新型药物向抵抗机制,为晚期疾病患者提供了新的希望.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是一个学科.

背景情况:

非小细胞肺癌 (NSCLC) 的死亡率很高,常见的表皮生长因子受体 (EGFR) 突变可以通过向疗法治疗.
不常见的EGFR突变和对现有疗法获得的耐药性 (例如C797S) 限制了治疗的有效性.
耐药性机制包括耐药性持久细胞,染色体不稳定性和染色体外细胞外DNA (ecDNA).

研究的目的:

评估第四代EGFR抑制剂对NSCLC常见和不常见EGFR突变的疗效.
调查BDTX-1535在克服抵抗机制方面的潜力,包括C797S突变.
探索对EGFR-氨酸激酶抑制剂 (TKI) 获得耐药性的NSCLC患者的新疗法.

主要方法:

对BDTX-1535进行临床前评估,BDTX-1535是一种口服生物可用,穿透大脑,不可逆转的EGFR抑制剂.
测试BDTX-1535对常见和不常见的EGFR突变组进行测试,包括像C797S和T790M这样的耐药性突变.
在NSCLC和质母细胞瘤的实验模型中评估BDTX-1535活性.

主要成果:

在临床前模型中,BDTX-1535显示出显著的抗瘤活性.
它抑制了常见的EGFR突变和50多种不常见的突变,包括T790M和C797S.
虽然BDTX-1535对外细胞域突变有潜力克服 osimertinib 耐药性和活性,但对外子 20 插入的效果较差.

结论:

第四代EGFR抑制剂,如BDTX-1535,代表了对NSCLC的有希望的治疗进展.
这些新型药物可以向各种EGFR突变,克服关键的抵抗机制,包括C797S.
需要进一步进行临床研究,以确定BDTX-1535在治疗复杂耐药性特征的NSCLC中的作用.

关键词:

C797SS 这是一个很好的例子.非小细胞肺癌 (NSCLC) 是一种非小细胞肺癌.驱动器突变驱动器突变新型药物新型药物阻力机制的阻力机制

更多相关视频

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...